FY2029 EPS Estimate for Moderna Cut by Analyst

Key Points

• Brookline Capital Markets lowered its FY2029 EPS forecast for Moderna to $11.40 from $11.54, while maintaining a Buy rating; it estimates FY2030 EPS at $18.03.
• Moderna reported quarterly EPS of $0.38, beating the $1.10-per-share loss analysts expected, and revenue of $1.31 billion versus estimates of $890.25 million. Revenue grew 29.2% year over year.
• Analyst sentiment overall remains mixed: MarketBeat reports a consensus Hold rating and $113.75 average price target, with six Buy, 15 Hold, and four Sell ratings.

Moderna, Inc. (NASDAQ:MRNA - Free Report) - Analysts at Brookline Capital Markets cut their FY2029 earnings per share estimates for Moderna in a research note issued on Friday, November 6th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $11.40 per share for the year, down from their prior estimate of $11.54. Brookline Capital Markets has a "Buy" rating on the stock. The consensus estimate for Moderna's current full-year earnings is ($6.11) per share. Brookline Capital Markets also issued estimates for Moderna's FY2030 earnings at $18.03 EPS.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm's revenue was up 29.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.51) earnings per share.

Several other research firms have also commented on MRNA. Piper Sandler restated an "overweight" rating and issued a $305.00 price target (up from $230.00) on shares of Moderna in a report on Monday. Wolfe Research raised shares of Moderna from an "underperform" rating to a "peer perform" rating in a research report on Tuesday, August 25th. Singular Research upgraded shares of Moderna to a "hold" rating in a research note on Wednesday, September 23rd. Morgan Stanley increased their price objective on shares of Moderna from $89.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Finally, Sanford C. Bernstein reissued a "market perform" rating on shares of Moderna in a research report on Friday, September 25th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, Moderna has a consensus rating of "Hold" and a consensus target price of $113.75.

Moderna Stock Up 5.8%

Shares of NASDAQ:MRNA opened at $269.00 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna has a 1 year low of $22.28 and a 1 year high of $280.80. The stock has a market capitalization of $107.40 billion, a P/E ratio of -37.89 and a beta of 1.16. The stock has a 50-day simple moving average of $194.47 and a 200-day simple moving average of $92.61.

Insider Buying and Selling

In related news, CFO Jamey Mock sold 34,836 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares of the company's stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the firm's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company's stock, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently bought and sold shares of MRNA. BlackRock Inc. acquired a new stake in shares of Moderna during the 2nd quarter valued at approximately $2,142,877,000. Theleme Partners LLP acquired a new position in Moderna in the second quarter valued at approximately $564,272,000. Merck & Co. Inc. acquired a new position in Moderna in the second quarter valued at approximately $161,642,545. Bamco Inc. NY bought a new position in shares of Moderna during the second quarter valued at approximately $139,317,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Moderna during the second quarter valued at approximately $119,168,000. 75.33% of the stock is owned by institutional investors.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
• Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
• Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.